ClinicalTrials.gg
CompletedNCT01144728AMIT KZUpdated Jan 31, 2011

Initiation and Titration of Amaryl

A Phase 4 interventional study of GLIMEPIRIDE + METFORMIN in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Kazakhstan. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-31.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
172
Allocation
Not applicable
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
25th of 52
172 · median 169
Started
2010
with 2 others
Phase 4
24 of 52
none open now
Registered
22nd of 52
by date
Lead sponsor
9 of 52
Sanofi

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 3 that started in 2010, is one of 24 in phase 4, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

  • To describe the conditions of initiation and titration of Amaryl M, according to previous treatment:
  • initial dose
  • titration scheme
  • efficacy after 4 months assessed by HbA1C
  • tolerability (number and severity of hypoglycaemia)

Secondary Objective:

  • Fasting Plasma Glucose
  • Weight evolution
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 2 diabetes who have been treated with a stable dose (any dose) of :
  • sulfonylurea monotherapy or
  • metformin monotherapy or
  • free combination of glimepiride and metformin with a stable dose (any dose)
  • (BMI) between 20 and 40 kg/m2
  • superior or egal to 7.5%
  • FPG superior or egal 7 mmol/l

Exclusion criteria

Exclusion criteria:

  • Secondary or insulin-dependant diabetes
  • Any severe chronic disease (hepatic, renal impairments)
  • History of major cardiovascular event in the last 6 months
  • Acute conditions with the potential to alter renal function such as: dehydratation, severe infection, shock, IV administration of iodinated contrast agents
  • Allergy to sulfonylurea, metformin
  • Drug or alcohol abuse
  • Pregnancy, lactation

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Single arm Glimepiride+metformin

    Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.

    Drug: GLIMEPIRIDE + METFORMIN

Interventions

  • DrugGLIMEPIRIDE + METFORMIN

    Drug pages: Glimepiride · Metformin

    Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500

06

What researchers measure

Primary outcomes

  1. Glycolysated Haemoglobin (HbA1c)

    Time frame: From baseline to Month 4

  2. Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%

    Time frame: Month 4

  3. Evolution of Fasting Plasma Glucose (FPG)

    Time frame: From baseline to Months 4

Secondary outcomes

  1. Post Prandial Plasma Glucose (PPPG)

    Time frame: Month 4

  2. Number of patients for each start dose

    Time frame: At baseline

  3. Number of patients with different final doses

    Time frame: Month 4

  4. Rate of Symptomatic Hypoglycemia

    Time frame: During treatment period (4 months)

  5. Change in Weight

    Time frame: Month 4

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Almaty, Kazakhstan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 16, 2010
Start
May 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Last update
Jan 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01144728
Lead sponsor
Sanofi
First posted
Jun 16, 2010
Start date
May 2010
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Jan 31, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Metformin

Start the discussion